Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Methyl 4-piperidineacetate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

168986-49-0

Post Buying Request

168986-49-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

168986-49-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 168986-49-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,8,9,8 and 6 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 168986-49:
(8*1)+(7*6)+(6*8)+(5*9)+(4*8)+(3*6)+(2*4)+(1*9)=210
210 % 10 = 0
So 168986-49-0 is a valid CAS Registry Number.
InChI:InChI=1/C8H15NO2/c1-9-4-2-7(3-5-9)6-8(10)11/h7H,2-6H2,1H3,(H,10,11)/p-1

168986-49-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name Methyl 4-Piperidineacetate

1.2 Other means of identification

Product number -
Other names Methyl piperidin-4-ylacetate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:168986-49-0 SDS

168986-49-0Relevant articles and documents

BROAD SPECTRUM ANTI-CANCER COMPOUNDS

-

Page/Page column 328, (2021/04/23)

Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3/14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS

-

Page/Page column 154, (2019/11/12)

The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

-

Paragraph 1253; 1255, (2014/07/23)

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors

Rossi, Cristina,Porcelloni, Marina,D'Andrea, Piero,Fincham, Christopher I.,Ettorre, Alessandro,Mauro, Sandro,Squarcia, Antonella,Bigioni, Mario,Parlani, Massimo,Nardelli, Federica,Binaschi, Monica,Maggi, Carlo A.,Fattori, Daniela

scheme or table, p. 2305 - 2308 (2011/05/15)

We report here the strategy used in our research group to find a new class of histone deacetylase (HDAC) inhibitors. A series of N-substituted 4-alkylpiperazine and 4-alkylpiperidine hydroxamic acids, corresponding to the basic structure of HDAC inhibitors (zinc binding moiety-linker-capping group) has been designed, prepared, and tested for HDAC inhibition. Linker length and aromatic capping group connection were systematically varied to find the optimal geometric parameters. A new series of submicromolar inhibitors was thus identified, which showed antiproliferative activity on HCT-116 colon carcinoma cells.

Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents

Wei, Linyi,Shi, Qian,Bastow, Kenneth F.,Brossi, Arnold,Morris-Natschke, Susan L.,Nakagawa-Goto, Kyoko,Wu, Tian-Shung,Pan, Shiow-Lin,Teng, Che-Ming,Lee, Kuo-Hsiung

, p. 3674 - 3680 (2008/02/10)

C9-Substituted phenanthrene-based tylophorine derivatives (PBTs) (13-36) were synthesized and evaluated as in vitro anticancer agents against the human A549 lung cancer cell line. Twelve active compounds were further examined against DU-145 (prostate), ZR-751 (breast), KB (nasopharyngeal), and KB-Vin (multidrug resistant KB subline) human cancer cell lines. They showed potent cytotoxic activity against both wild type and matched multidrug resistant KB cell lines, and displayed notable selectivity toward DU-145 (prostate) and ZR-751 (breast) cancer cell lines. The mode of action of this class may be distinctly different from that of other cancer chemotherapeutic compounds. Three PBT analogs were also evaluated in a murine model. Compound 24b showed modest in vivo antitumor activity against human A549 xenograft in nude mice as well as potent in vitro cytotoxic activity, and thus, is a promising anticancer lead compound.

ACTIVE KETONE INHIBITORS OF TRYPTASE

-

Page/Page column 123-124, (2008/06/13)

The present invention related to certain active tetracyclic ketone inhibitors of tryptase, pharmaceutical composition comprising these compounds and methods of treating asthma, allergic rhinitis, and/or Chronic Obstructive Pulmonary Disease utilizing thes

Development of new non-peptide GPIIb-IIIa antagnosts, NSL-95315 and NSL-95317, isosteres of NSL-95300

Asari, Tohru,Ishikawa, Shigetaka,Sasaki, Toshiki,Katada, Jun,Hayashi, Yoshio,Harada, Takeo,Yano, Mako,Yasuda, Emiko,Uno, Isao,Ojima, Iwao

, p. 2099 - 2104 (2007/10/03)

The synthetic and structure-activity relationship (SAR) studies of new non-peptide GPIIb/IIIa antagonists (1a-f and 3) were conducted by replacing one amide bond of NSL-95300 (2) with an (E)-double bond or an enone group. NSL-95315 (1a) and NSL-95317 (3) showed the inhibitory activity for collagen-induced human platelet aggregation with IC50 values of 0.25 μM and 0.21 μM, respectively.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 168986-49-0